Biosense Webster Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biosense Webster Inc
Results from two industry-supported clinical trials published in the last week offer more support for treating atrial fibrillation with catheter ablation rather than medication alone.
Johnson & Johnson plans to buy Abiomed for $380 per share – about $16.6bn in total – plus up to $35 per share in potential commercial and clinical milestone-contingent payments. Abiomed is the clear leader in percutaneous circulatory support technology, but would benefit from J&J's reach and resources while complementing J&J's Biosense Webster electrophysiology business.
In Part II of Medtech Insight’s extensive interview, Michael Bodner, the worldwide president of Johnson & Johnson/Biosense Webster, talked about the company’s vision for electrophysiology beyond the first generation of pulsed field ablation and the company’s commitment to improving diversity and inclusion.
Medtech Insight talked to Michael Bodner, the worldwide president of Johnson & Johnson/Biosense Webster, about the company’s plans to stay number one in the cardiac ablation market. In part 1 of the interview, the medtech veteran talked about the company's plan to compete in the crowded pulsed field ablation field.
- Diagnostic Imaging Equipment & Supplies
Surgical Equipment & Devices
- Minimally or Less Invasive